(Q27692640)

Rogier M. Thurlings

series ordinal

2

1 reference

Danielle M. Gerlag

series ordinal

3

1 reference

Koen Vos

series ordinal

4

1 reference

publication date

November 2011

1 reference

published in

Arthritis & Rheumatology

1 reference

volume

63

1 reference

issue

11

1 reference

page(s)

3187-94

1 reference

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

cites work

1 reference

Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers

21 January 2018

1 reference

Cell to cell interaction in the immune response. II. The source of hemolysin-forming cells in irradiated mice given bone marrow and thymus or thoracic duct lymphocytes

21 January 2018

1 reference

Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice

21 January 2018

1 reference

Regulatory roles for cytokine-producing B cells in infection and autoimmune disease

21 January 2018

1 reference

Plasmacytoid dendritic cells regulate autoreactive B cell activation via soluble factors and in a cell-to-cell contact manner

21 January 2018

1 reference

B lymphocytes: how they develop and function.

21 January 2018

1 reference

Competence and competition: the challenge of becoming a long-lived plasma cell

21 January 2018

1 reference

Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice.

21 January 2018

1 reference

Autoantibodies in rheumatoid arthritis and their clinical significance

21 January 2018

1 reference

Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells

21 January 2018

1 reference

Anti-citrullinated protein antibodies bind surface-expressed citrullinated Grp78 on monocyte/macrophages and stimulate tumor necrosis factor alpha production

21 January 2018

1 reference

Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen

21 January 2018

1 reference

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

21 January 2018

1 reference

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium

21 January 2018

1 reference

Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype

21 January 2018

1 reference

B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy

21 January 2018

1 reference

Depletion of functionally active CD20+ T cells by rituximab treatment

21 January 2018

1 reference

Mice carrying a CD20 gene disruption

21 January 2018

1 reference

The biology of CD20 and its potential as a target for mAb therapy

21 January 2018

1 reference

CD20 deficiency in humans results in impaired T cell-independent antibody responses

21 January 2018

1 reference

Mechanisms of killing by anti-CD20 monoclonal antibodies.

21 January 2018

1 reference

Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention

21 January 2018

1 reference

The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice.

21 January 2018

1 reference

Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis

21 January 2018

1 reference

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

21 January 2018

1 reference

Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment

21 January 2018

1 reference

Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment

21 January 2018

1 reference

Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis

21 January 2018

1 reference

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients

21 January 2018

1 reference

Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production

21 January 2018

1 reference

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

21 January 2018

1 reference

Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity

21 January 2018

1 reference

Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab

21 January 2018

1 reference

Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response

21 January 2018

1 reference

Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.

21 January 2018

1 reference

Rituximab-induced changes in hematolymphoid tissues found at autopsy

21 January 2018

1 reference

Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis

21 January 2018

1 reference

Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis

21 January 2018

1 reference

Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results

21 January 2018

1 reference

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response

21 January 2018

1 reference

The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases

21 January 2018

1 reference

Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis

21 January 2018

1 reference

Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis

21 January 2018

1 reference

Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers

21 January 2018

1 reference

C5A anaphylatoxin and its seven transmembrane-segment receptor

21 January 2018

1 reference

Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase

21 January 2018

1 reference

Complement and cellular cytotoxicity in antibody therapy of cancer

21 January 2018

1 reference

Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation

21 January 2018

1 reference

Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.30567

0 references

PubMed publication ID

21792840

1 reference